HilleVax, Inc.

NasdaqGS HLVX

HilleVax, Inc. Inventory for the quarter ending September 30, 2024: USD 0.00

HilleVax, Inc. Inventory is USD 0.00 for the quarter ending September 30, 2024, a 100.00% change year over year. Inventory is the value of goods held by a company for sale or used in the production process.

HilleVax, Inc. Inventory for the quarter ending September 30, 2023 was USD -8.79 M.

Key data

Date	Inventory	Goodwill	Total Assets	Current Liabilities

NasdaqGS: HLVX

HilleVax, Inc.

CEO	Dr. Robert M. Hershberg M.D., Ph.D.
IPO Date	April 29, 2022
Location	United States
Headquarters	75 State Street
Employees	90
Sector	Healthcare
Industries Vaccines Biotechnology Pharmaceuticals

Description

HilleVax, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing novel vaccines. It is developing HIL-214, a virus-like particle-based vaccine candidate for the prevention of moderate-to-severe acute gastroenteritis caused by norovirus infection. The company is headquartered in Boston, Massachusetts.

Key trends

Past 5 years